Abstract
Objective To investigate efficacy and tolerability of nimotuzumab in combination with three dimensional conformal radiotherapy in recurrent nasopharyngeal carcinoma.Methods 32 cases of recurrent nasopharyngeal carcinoma were randomly divided into control group and experimental group,16 cases in each group.Control group was treated with conventional concomitant fractionated radiation (60-70 Gy in 2 Gy fractions) and 2 cycles of cisplatin 20 mg/m2 (d1-4) every 3 weeks.Nimotuzumab was added at a dose of 100 mg i.v.weekly for 6-7 weeks at the beginning of radiotherapy in experimental group.Results The response rate (RR) and the disease control rate (DCR) of control group were 43.75％ and 68.75％ respectively,while those of experimental group were 50％ and 75％ respectively,without significant differences between two groups.The most common reported adverse events were lymphopenia and gastrointestinal reactions,with significant difference between two groups.The most frequent nimotuzumab-related adverse events were fever (25％),hypotension (18.75％) and rash (18.75％),which didn' t disturb the therapy.Conclusion Nimotuzumab in combination with three dimensional conformal radiotherapy is well-tolerated and feasible for recurrent nasopharyngeal carcinoma,worthy of clinical application. Key words: Recurrent nasopharyngeal carcinoma; Nimotuzumab; Three dimensional conformal radiotherapy; Cisplatin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
